DV
Dividend Vision

BBLG — Bone Biologics Corp

Bone Biologics Corp (BBLG)

Total return is -84.0% over the past 10.4 years, 429.8 points behind SPY at 345.8%. Its deepest 1-year drawdown was 76.9%.

BBLG is an equity fund focused on stock investments, with an inception date of March 2016. The fund does not currently offer distributions, making it unsuitable for income-focused investors seeking regular dividend payments. Limited data is available on expense ratio, assets under management, and detailed investment objective, which constrains a full assessment of its characteristics and appeal profile.

BBLG key facts

Asset type
Stock
Asset class
Equity
Inception date
03/31/2016
Last close
$0.66
Market cap
$2,100,454
Average volume
171700.0
Payment date
07/24/2018
Beta
0.531
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.16